Cutting cravings
The former executive team from CV Therapeutics Inc. are treading familiar ground with an addiction program licensed from Gilead Sciences Inc. Newco Amygdala Neurosciences Inc. aims to develop ANS-6673 to treat substance abuse disorders currently...